Objective: The purpose of this study was to determine whether amniotic fluid levels of annexinA5 (AF- AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design:Amniotic fluid was obtained in a...Objective: The purpose of this study was to determine whether amniotic fluid levels of annexinA5 (AF- AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design:Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks gestation and annexin A5 (AnxA5) levels were determined with enzyme linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results:AF- AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF- AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF- AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR(P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF- AnxA5 may be a useful marker for identifying pregnancy abnormalities.展开更多
文摘Objective: The purpose of this study was to determine whether amniotic fluid levels of annexinA5 (AF- AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design:Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks gestation and annexin A5 (AnxA5) levels were determined with enzyme linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results:AF- AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF- AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF- AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR(P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF- AnxA5 may be a useful marker for identifying pregnancy abnormalities.
